|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C12N 9/64 | (2006.01) |
| (11) | Number of the document | 3411478 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17705236.2 |
| Date of filing the European patent application | 2017-01-31 | |
| (97) | Date of publication of the European application | 2018-12-12 |
| (45) | Date of publication and mention of the grant of the patent | 2022-06-08 |
| (46) | Date of publication of the claims translation | 2022-09-26 |
| (86) | Number | PCT/US2017/015879 |
| Date | 2017-01-31 |
| (87) | Number | WO 2017/136358 |
| Date | 2017-08-10 |
| (30) | Number | Date | Country code |
| 201662289696 P | 2016-02-01 | US | |
| 201662409739 P | 2016-10-18 | US |
| (72) |
TAN, Siyuan , US
LIU, Tongyao , US
|
| (73) |
Bioverativ Therapeutics Inc. ,
225 Second Avenue, Waltham, MA 02451,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Optimizuoti VIII faktoriaus genai |
| OPTIMIZED FACTOR VIII GENES |
| Payment date | Validity (years) | Amount | |
| 2025-12-22 | 10 | 231.00 EUR |
| 2027-01-31 |